Ga direct naar de inhoud

Ga direct naar de navigatie

Uitgave van

Berichten met het trefwoord ‘AbbVie’

Boehringer Ingelheim presents phase III results demonstrating clinical equivalence of biosimilar to Humira

Boehringer Ingelheim has announced results from the pivotal Phase III VOLTAIRE®-RA(1) study, confirming that its adalimumab biosimilar candidate BI 695501 and HUMIRA®* have similar efficacy, safety and immunogenicity in patients with moderately-to-severely active rheumatoid arthritis. The 24 week results will be presented at the Annual European Congress of Rheumatology (EULAR 2017) in Madrid.

Bron: World Pharma News Meer lezen »

AbbVie, Novo, Takeda take home honors in pharma’s latest reputation study

Which pharma company has the best reputation? Boston-based Reputation Institute has a few ideas. A study based on more than 16,500 reputation ratings collected throughout the U.S., Europe and Brazil during the first two months of this year has ranked AbbVie No. 1.

Bron: FiercePharma Meer lezen »

AbbVie cancer drug fails two late-stage trials

AbbVie Inc said on Wednesday that its experimental cancer drug, veliparib, failed to meet the main goals of two late-stage studies. The trials evaluated the effect of veliparib, in combination with a chemotherapy regimen, on patients with non-small cell lung cancer (NSCLC) and triple-negative breast cancer.

Bron: Reuters Meer lezen »

AbbVie’s Humira needs a discount, ICER says, warning Lilly, Sanofi to price with care

The best-selling drug in the world isn’t worth its current price—and isn’t as good at its job as two of its potential competitors. That’s the conclusion of the Institute for Clinical and Economic Review, a cost-effectiveness watchdog, which evaluated rheumatoid arthritis drugs and found AbbVie’s Humira wanting.

Bron: FiercePharma Meer lezen »

Phase 3 data for Janssen psoriasis drug shows efficacy over Humira

Janssen has revealed new Phase 3 data for its human monoclonal antibody guselkumab in the treatment of adults with moderate to severe plaque psoriasis, showing the drug to produce significant efficacy compared to Abbvie’s blockbuster drug and market leader Humira (adalimumab).  

Bron: Meer lezen »

FDA panel backs Amgen copy of AbbVie arthritis drug Humira

 Amgen Inc’s cheaper version of AbbVie’s top-selling arthritis drug Humira is highly similar to the original and should be approved, an advisory panel to the U.S. Food and Drug Administration concluded on Tuesday.

Bron: Reuters Meer lezen »

Amgen’s Humira biosim ‘highly similar’ to AbbVie original, FDA staffers say

  Things look good for Amgen heading into a Tuesday advisory committee meeting on its Humira biosimilar candidate. In briefing documents released Friday, FDA staffers said that their review of data from rheumatoid arthritis and plaque psoriasis trials of the prospect–dubbed ABP 501–suggested Amgen’s copy was “highly similar” to Humira, an AbbVie drug that currently tops […]

Bron: FiercePharma Meer lezen »

European pharma ‘to grow 3.2% per year by 2022’

Forecast predicts AbbVie’s Humira will be knocked off the top spot.

Bron: PMLiVE Meer lezen »

Newest Imbruvica ‘breakthrough’ tag gives J&J, AbbVie hope for expansion outside blood cancers

Johnson & Johnson and AbbVie have been charging hard to rack up additional indications for star med Imbruvica in hematologic cancers. But with the med’s latest breakthrough designation, there’s hope for the pair expanding Imbruvica’s patient pool outside that area, too.

Bron: FiercePharma Meer lezen »

Trial of AbbVie’s Rova-T disappoints at ASCO

A cancer drug licensed by AbbVie in a $5.8bn deal has failed to impress at this year’s ASCO conference, sending the company’s shares into decline.

Bron: PMLiVE Meer lezen »

« Oudere artikelen |